Prof. Dr. med. Michael Hölzel

Curriculum Vitae

A.) General information

Name: **Prof. Dr. med. Michael Hölzel**
Address: Institut für Klinische Chemie
und Klinische Pharmakologie
Zentrallabor
Universitätsklinikum Bonn
Sigmund-Freud-Str. 25
53127 Bonn

Phone: 0228-287-12170
Fax: 0228-287-12159
E-mail: michael.hoelzel@ukb.uni-bonn.de

Date of birth: 01.03.1976
Nationality: German

B.) Scientific career

Education/Degrees:

1996-2003 Medical School, Ludwig-Maximilians-University, Munich

Clinical and research experience:

2003-2005 Residency in Hematology/Oncology, Klinikum Grosshadern, Munich

2000-2006 MD thesis (2004) and Research Assistant in the laboratory of Prof. Dirk Eick, Helmholtz Research Center, Munich

2007-2011 Post-doc in the laboratory of Professor René Bernards, The Netherlands Cancer Institute (NKI), Amsterdam

since 2012 Institute of Clinical Chemistry and Clinical Pharmacology

Appointment:

June 2012 W2-Professorship for RNA-Biology

C.) 5 most important scientific publications

1. **Hölzel, M.**, Rohrmoser, M., Schlee, M., Grimm, T., Harasim, T., Malamoussi, A., Gruber-Eber, A., Kremmer, E., Hiddemann, W., Bornkamm, GW., Eick, D. **(2005)** Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation. ***J Cell Biol.*** *170*, 367-78.
2. **Hölzel, M**., Huang, S., Koster, J., Ora, I., Lakeman, A., Caron, H., Nijkamp, W., Xie, J., Callens, T., Asgharzadeh, S., Seeger, RC., Messiaen, L., Versteeg, R., Bernards, R. **(2010)**. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. ***Cell*** *142*, 218–229.
3. **Hölzel, M**., Orban, M., Hochstatter, J., Rohrmoser, M., Harasim, T., Malamoussi, A., Kremmer, E., Längst, G., and Eick, D. **(2010)**. Defects in 18 S or 28 S rRNA processing activate the p53 pathway. ***J. Biol. Chem***. *285*, 6364–6370.
4. Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., **Hölzel, M**., Tüting, T. **(2012)**. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. ***Nature*** *490*, 412–416.
5. Huang, S., **Hölzel, M**., Knijnenburger, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M.J., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F.H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., Ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R.L., Wessels, L.F., Bernards, R. **(2012)**. MED12 controls the response to multiple cancer drugs through regulation of TGFβ receptor signaling. ***Cell*** *151*(5), 937–950.